(Total Views: 550)
Posted On: 07/02/2023 4:05:16 PM
Post# of 148887
A route for LL?
Foundation charges cancer patients $83,000 for unproven but promising experimental drug
Could this be a route for LL until approval?
This is a process for folks that are out of options getting treatment through compassionate use. Controversial as the patient pays big time for the full expenses.
FDA preferred process is clinical trials- but as the article states- many patients are not able to get into trials and are excluded from participating. (I know this personally to be true.)
Could our Dr Jay be a link to this?
(Full disclosure: have a deep respect and admiration for him as a result of trying to get a friend into the LL cancer trial a few years ago.)
The last part of the article is the most informative and adds:
'A doctor at Duke was skeptical and would not administer the shots, Kielty said. Kielty plans to travel soon to San Francisco to Quest Clinical Research , the same clinic where Young, the retired businesswoman with ovarian cancer, gets her shots.'
Foundation charges cancer patients $83,000 for unproven but promising experimental drug
Could this be a route for LL until approval?
This is a process for folks that are out of options getting treatment through compassionate use. Controversial as the patient pays big time for the full expenses.
FDA preferred process is clinical trials- but as the article states- many patients are not able to get into trials and are excluded from participating. (I know this personally to be true.)
Could our Dr Jay be a link to this?
(Full disclosure: have a deep respect and admiration for him as a result of trying to get a friend into the LL cancer trial a few years ago.)
The last part of the article is the most informative and adds:
'A doctor at Duke was skeptical and would not administer the shots, Kielty said. Kielty plans to travel soon to San Francisco to Quest Clinical Research , the same clinic where Young, the retired businesswoman with ovarian cancer, gets her shots.'
(7)
(0)Scroll down for more posts ▼
